NCT02911142 2025-07-28
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)